vs
CISO Global, Inc.（CISO）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是CISO Global, Inc.的1.5倍（$9.1M vs $6.3M），CISO Global, Inc.净利率更高（-35.4% vs -60.3%，领先25.0%），CISO Global, Inc.同比增速更快（-15.4% vs -49.9%），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -11.6%）
CISO Global Inc.是专业网络安全服务商，提供托管安全监测、风险评估、合规咨询、事件响应、终端防护等服务，面向北美市场的中小企业、政府机构及商业客户，覆盖医疗、零售、金融等领域，助力客户保护数字资产、抵御网络风险。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CISO vs PLX — 直观对比
营收规模更大
PLX
是对方的1.5倍
$6.3M
营收增速更快
CISO
高出34.6%
-49.9%
净利率更高
CISO
高出25.0%
-60.3%
两年增速更快
PLX
近两年复合增速
-11.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.3M | $9.1M |
| 净利润 | $-2.2M | $-5.5M |
| 毛利率 | 28.6% | 49.4% |
| 营业利润率 | -33.7% | -51.1% |
| 净利率 | -35.4% | -60.3% |
| 营收同比 | -15.4% | -49.9% |
| 净利润同比 | 59.8% | -184.8% |
| 每股收益（稀释后） | $0.10 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CISOPLX
| Q4 25 | $6.3M | $9.1M | ||
| Q3 25 | $6.5M | $17.9M | ||
| Q2 25 | $6.7M | $15.7M | ||
| Q1 25 | $7.2M | $10.1M | ||
| Q4 24 | $7.4M | $18.2M | ||
| Q3 24 | $7.5M | $18.0M | ||
| Q2 24 | $7.8M | $13.5M | ||
| Q1 24 | $8.0M | — |
净利润CISOPLX
| Q4 25 | $-2.2M | $-5.5M | ||
| Q3 25 | $2.5M | $2.4M | ||
| Q2 25 | $-3.0M | $164.0K | ||
| Q1 25 | $-5.4M | $-3.6M | ||
| Q4 24 | $-5.5M | $6.5M | ||
| Q3 24 | $-3.7M | $3.2M | ||
| Q2 24 | $-8.4M | $-2.2M | ||
| Q1 24 | $-6.6M | — |
毛利率CISOPLX
| Q4 25 | 28.6% | 49.4% | ||
| Q3 25 | 24.9% | 53.4% | ||
| Q2 25 | 24.4% | 62.5% | ||
| Q1 25 | 24.9% | 19.1% | ||
| Q4 24 | 24.8% | 78.7% | ||
| Q3 24 | 13.8% | 53.4% | ||
| Q2 24 | 12.0% | 29.8% | ||
| Q1 24 | 8.8% | — |
营业利润率CISOPLX
| Q4 25 | -33.7% | -51.1% | ||
| Q3 25 | -40.8% | 11.9% | ||
| Q2 25 | -34.7% | 7.5% | ||
| Q1 25 | -23.9% | -41.0% | ||
| Q4 24 | -26.1% | 39.6% | ||
| Q3 24 | -46.8% | 22.2% | ||
| Q2 24 | -54.3% | -18.0% | ||
| Q1 24 | -61.0% | — |
净利率CISOPLX
| Q4 25 | -35.4% | -60.3% | ||
| Q3 25 | 39.2% | 13.2% | ||
| Q2 25 | -44.8% | 1.0% | ||
| Q1 25 | -75.1% | -35.8% | ||
| Q4 24 | -74.5% | 35.6% | ||
| Q3 24 | -49.0% | 18.0% | ||
| Q2 24 | -108.0% | -16.4% | ||
| Q1 24 | -82.4% | — |
每股收益（稀释后）CISOPLX
| Q4 25 | $0.10 | $-0.06 | ||
| Q3 25 | $-0.05 | $0.03 | ||
| Q2 25 | $-0.09 | $0.00 | ||
| Q1 25 | $-0.38 | $-0.05 | ||
| Q4 24 | $-0.47 | $0.10 | ||
| Q3 24 | $-0.32 | $0.03 | ||
| Q2 24 | $-0.69 | $-0.03 | ||
| Q1 24 | $-0.55 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $14.8M | $48.2M |
| 总资产 | $25.0M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CISOPLX
| Q4 25 | $1.7M | $14.7M | ||
| Q3 25 | $1.1M | $13.6M | ||
| Q2 25 | $760.8K | $17.9M | ||
| Q1 25 | $1.8M | $19.5M | ||
| Q4 24 | $992.6K | $19.8M | ||
| Q3 24 | $443.1K | $27.4M | ||
| Q2 24 | $1.1M | $23.4M | ||
| Q1 24 | $1.5M | — |
总债务CISOPLX
| Q4 25 | — | — | ||
| Q3 25 | $2.1M | — | ||
| Q2 25 | $9.9M | — | ||
| Q1 25 | $10.6M | — | ||
| Q4 24 | $11.7M | — | ||
| Q3 24 | $11.9M | — | ||
| Q2 24 | $12.8M | — | ||
| Q1 24 | $15.1M | — |
股东权益CISOPLX
| Q4 25 | $14.8M | $48.2M | ||
| Q3 25 | $16.3M | $52.9M | ||
| Q2 25 | $7.6M | $49.9M | ||
| Q1 25 | $7.0M | $45.2M | ||
| Q4 24 | $1.1M | $43.2M | ||
| Q3 24 | $3.0M | $32.4M | ||
| Q2 24 | $5.6M | $28.6M | ||
| Q1 24 | $11.2M | — |
总资产CISOPLX
| Q4 25 | $25.0M | $82.3M | ||
| Q3 25 | $25.1M | $82.3M | ||
| Q2 25 | $25.8M | $78.5M | ||
| Q1 25 | $27.8M | $73.9M | ||
| Q4 24 | $26.7M | $73.4M | ||
| Q3 24 | $26.6M | $61.6M | ||
| Q2 24 | $43.2M | $91.5M | ||
| Q1 24 | $47.5M | — |
负债/权益比CISOPLX
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.52× | — | ||
| Q4 24 | 10.20× | — | ||
| Q3 24 | 3.92× | — | ||
| Q2 24 | 2.27× | — | ||
| Q1 24 | 1.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.8M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CISOPLX
| Q4 25 | $-1.8M | $2.0M | ||
| Q3 25 | $-876.7K | $-3.7M | ||
| Q2 25 | $-2.3M | $-5.2M | ||
| Q1 25 | $-3.0M | $-5.1M | ||
| Q4 24 | $-259.0K | $4.0M | ||
| Q3 24 | $-903.1K | $4.1M | ||
| Q2 24 | $-1.3M | $-3.6M | ||
| Q1 24 | $-1.4M | — |
自由现金流CISOPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $-1.3M | $-3.8M | ||
| Q1 24 | $-1.5M | — |
自由现金流率CISOPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | -16.4% | -28.1% | ||
| Q1 24 | -18.5% | — |
资本支出强度CISOPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.9% | — |
现金转化率CISOPLX
| Q4 25 | — | — | ||
| Q3 25 | -0.35× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CISO
| Security Managed Services | $5.4M | 87% |
| Other | $823.3K | 13% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
